Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,747,285
  • Shares Outstanding, K 173,085
  • Annual Sales, $ 307,710 K
  • Annual Income, $ -96,690 K
  • 36-Month Beta 2.79
  • Price/Sales 6.24
  • Price/Cash Flow N/A
  • Price/Book 4.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.70
  • Number of Estimates 6
  • High Estimate -0.61
  • Low Estimate -0.80
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.22 +48.70%
on 12/24/18
46.79 -7.14%
on 01/22/19
+12.83 (+41.90%)
since 12/21/18
3-Month
29.22 +48.70%
on 12/24/18
46.79 -7.14%
on 01/22/19
+3.95 (+10.00%)
since 10/23/18
52-Week
29.22 +48.70%
on 12/24/18
111.36 -60.98%
on 03/12/18
-34.34 (-44.14%)
since 01/23/18

Most Recent Stories

More News
Shares of NKTR Up 16.3% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Nektar Therapeut (NASDAQ:NKTR) on January 8th, 2019 at $38.59. In approximately 2 weeks, Nektar Therapeut has returned 16.27% as of today's recent price of $44.87.

NKTR : 43.84 (-2.06%)
Look for Shares of Nektar Therapeut to Potentially Pullback after Yesterday's 3.08% Rise

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $37.06 to a high of $38.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high...

NKTR : 43.84 (-2.06%)
Relatively Good Performance Detected in Shares of Lannett Co Inc in the Pharmaceuticals Industry (LCI , DERM , NKTR , MNK , PRGO )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

DERM : 6.15 (-3.45%)
LCI : 7.62 (-2.31%)
NKTR : 43.84 (-2.06%)
Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration

Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.

LLY : 118.01 (+0.79%)
PFE : 42.04 (-0.54%)
BMY : 50.09 (+0.74%)
NKTR : 43.84 (-2.06%)
ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics

ImaginAb Inc., an immuno-oncology imaging company, today announced that it has entered into a non-exclusive license and clinical trial collaboration with Nektar Therapeutics (Nasdaq: NKTR). Under the terms...

NKTR : 43.84 (-2.06%)
CLASS ACTION UPDATE for NKTR, FIT, WBT and XRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

FIT : 6.04 (-0.33%)
WBT : 13.14 (-0.53%)
XRAY : 40.95 (+0.47%)
NKTR : 43.84 (-2.06%)
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and...

NKTR : 43.84 (-2.06%)
NKTR FINAL DEADLINE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important December 31 Deadline in Class Action - NKTR

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period")...

NKTR : 43.84 (-2.06%)
BioXcel Surges on Fast Track Designation to Agitation Drug

BioXcel (BTAI) soars after the FDA granted Fast Track designation to its lead candidate, BXCL501.

BTAI : 5.58 (-2.62%)
MRK : 75.32 (-0.67%)
BMY : 50.09 (+0.74%)
NKTR : 43.84 (-2.06%)
Pawar Law Group Reminds of Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

NEW YORK, NY / ACCESSWIRE / December 28, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nektar Therapeutics (NASDAQ: NKTR)...

NKTR : 43.84 (-2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade NKTR with:

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 47.75
1st Resistance Point 46.26
Last Price 43.84
1st Support Level 43.80
2nd Support Level 42.83

See More

52-Week High 111.36
Fibonacci 61.8% 79.98
Fibonacci 50% 70.29
Fibonacci 38.2% 60.60
Last Price 43.84
52-Week Low 29.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar